Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern

Maggie Li, Evan J. Beck, Oliver Laeyendecker, Yolanda Eby, Aaron A.R. Tobian, Patrizio Caturegli, Camille Wouters, Gregory R. Chiklis, William Block, Robert O. McKie, Michael J. Joyner, Timothy D. Wiltshire, Allan B. Dietz, Thomas J. Gniadek, Arell J. Shapiro, Anusha Yarava, Karen Lane, Daniel F. Hanley, Evan M. Bloch, Shmuel ShohamEdward R. Cachay, Barry R. Meisenberg, Moises A. Huaman, Yuriko Fukuta, Bela Patel, Sonya L. Heath, Adam C. Levine, James H. Paxton, Shweta Anjan, Jonathan M. Gerber, Kelly A. Gebo, Arturo Casadevall, Andrew Pekosz, David J. Sullivan

Research output: Contribution to journalArticlepeer-review


The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants severely limits available effective monoclonal antibody therapies. Effective drugs are also supply limited. COVID-19 convalescent plasma (CCP) qualified for high antibody levels effectively reduces immunocompetent outpatient hospitalization. The Food and Drug Administration currently allows outpatient CCP for the immunosuppressed. Viral-specific antibody levels in CCP can range 10- to 100-fold between donors, unlike the uniform viral-specific monoclonal antibody dosing. Limited data are available on the efficacy of polyclonal CCP to neutralize variants. We examined 108 pre-d/pre-o donor units obtained before March 2021, 20 post-d COVID-19/postvaccination units, and 1 pre-d/pre-o hyperimmunoglobulin preparation for variant-specific virus (vaccine-related isolate [WA-1], d, and o) neutralization correlated to Euroimmun S1 immunoglobulin G antibody levels. We observed a two- to fourfold and 20- to 40-fold drop in virus neutralization from SARS-CoV-2 WA-1 to d or o, respectively.

Original languageEnglish (US)
Pages (from-to)3678-3683
Number of pages6
JournalBlood Advances
Issue number12
StatePublished - Jun 28 2022

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern'. Together they form a unique fingerprint.

Cite this